A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
about
Emerging Threats in Antifungal-Resistant Fungal PathogensFitness trade-offs restrict the evolution of resistance to amphotericin BSphingolipid biosynthetic pathway genes FEN1 and SUR4 modulate amphotericin B resistance.Analysis of hypoxia and hypoxia-like states through metabolite profiling.Clotrimazole as a potent agent for treating the oomycete fish pathogen Saprolegnia parasitica through inhibition of sterol 14α-demethylase (CYP51)Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B.Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme.FK520 interacts with the discrete intrahelical amino acids of multidrug transporter Cdr1 protein and acts as antagonist to selectively chemosensitize azole-resistant clinical isolates of Candida albicans.Triclosan antagonizes fluconazole activity against Candida albicans.Blue dye and red light, a dynamic combination for prophylaxis and treatment of cutaneous Candida albicans infections in mice.An Antifungal Benzimidazole Derivative Inhibits Ergosterol Biosynthesis and Reveals Novel Sterols.Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B.Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2.Sterol 14α-demethylase mutation leads to amphotericin B resistance in Leishmania mexicana.A common mechanism involving the TORC1 pathway can lead to amphotericin B-persistence in biofilm and planktonic Saccharomyces cerevisiae populations.Sterol C-22 Desaturase ERG5 Mediates the Sensitivity to Antifungal Azoles in Neurospora crassa and Fusarium verticillioidesMolecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitalsThe synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn.Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections.Mitigation of human-pathogenic fungi that exhibit resistance to medical agents: can clinical antifungal stewardship help?Antifungals: Mechanism of Action and Drug Resistance.Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus.Pathogenesis of Candida albicans biofilm.Sedaxicenes: potential new antifungal ferrocene-based agents?Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment.The effects of photodynamic treatment with new methylene blue N on the Candida albicans proteome.ERG11 mutations and expression of resistance genes in fluconazole-resistant Candida albicans isolates.Principles of a New Protocol for Prediction of Azole Resistance in Candida albicans Infections on the Basis of ERG11 PolymorphismsSynergistic and drug-resistant reversing effects of diorcinol D combined with fluconazole against Candida albicans.Co-production of ethanol and squalene using a Saccharomyces cerevisiae ERG1 (squalene epoxidase) mutant and agro-industrial feedstock.Co-production of 11α-hydroxyprogesterone and ethanol using recombinant yeast expressing fungal steroid hydroxylasesNSG2 (ORF19.273) Encoding Protein Controls Sensitivity of Candida albicans to Azoles through Regulating the Synthesis of C14-Methylated Sterols.Silver nanoparticles induced alterations in multiple cellular targets, which are critical for drug susceptibilities and pathogenicity in fungal pathogen (Candida albicans).Treatment of Invasive Candidiasis: A Narrative Review
P2860
Q26750816-18CB79D3-1F01-473B-9F66-FDB376E81C54Q28534687-65267370-85BE-4718-821E-87C0773A2ACDQ33622748-C11B0602-38BD-4C1E-9345-AF5D12A2E5CEQ34024015-980F5CA3-BF55-4A53-A4BF-A98D2B09E769Q34261359-6706E9AA-3313-451D-9601-847D40C9772DQ34290082-68B1A52A-C957-4EA8-9740-85D818B0D87FQ34290134-F6678D8C-1A6F-417C-A9D8-171207453053Q34597385-84588628-A38B-4A5D-AD4E-AF98F40C2E45Q35120697-D71BFD11-77FB-48EB-BF10-FB6EBB63B049Q35596548-23DC1DCE-0B71-436C-9267-F7E3C33A2545Q35598589-1BD696CA-6F13-422A-B1E2-C08792458167Q35739026-0C81F0C6-D00A-4853-B738-7D6551643873Q36171637-5AC38878-A5C3-4C04-AEE9-6E31C7775214Q36396182-D3AFFF4A-AB36-4F8B-BC4E-D27F7B7BCB4DQ36407342-6D112B4C-9805-41B9-8945-C62A8C6FE4F5Q36605876-F5E58BE4-BF60-4008-9C9B-48848AECAC6DQ36882388-805589B5-E5C3-4AFA-B40E-34D738136F64Q36969703-73425360-E220-477A-AAD4-8D81EC3B27F0Q37189877-BF447F9D-259D-4C9F-8F53-0DC179053313Q38103889-231C4B50-8C31-44C9-AE77-762D77E43D74Q38206867-19584842-C989-4C8A-A790-7E93612FD1A5Q38684281-7D231303-31A9-460D-85DF-1548AE01E42BQ38711698-55DE2D68-A1D8-4651-BD9D-7DD4F85A17AFQ38767464-A9675C42-8564-4CF6-B3C2-98D35F20B777Q38787319-7C66A66D-1D3C-4C9F-87DB-282B3304374DQ40040802-9E903C24-AA7C-4017-8D1B-ED58B48FCA61Q40457925-4CC25E4D-250C-44B6-89B0-1DBA2E7C6F25Q40562539-09DF7520-169F-45E1-9ACA-01A07385472CQ40701989-E49B5D1E-E68F-46CC-A143-C27ACF5B78F6Q41442442-6A145FBF-9B36-4B55-B57A-6D7DF67FBEB9Q42006247-42EA7C2A-1DAB-4131-8BC1-E388E294A416Q42368083-6FFD1DE2-642A-44FA-81C1-4A335448F3E1Q52668355-126E0177-375C-4C0D-AC66-A3D7807B18CDQ55422759-2205B55A-BFF1-4574-B8A9-1BA8A1D1E0C7Q58772447-12C840BD-B941-41E6-8548-F930120B6670
P2860
A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A clinical isolate of Candida ...... to azoles and amphotericin B.
@ast
A clinical isolate of Candida ...... to azoles and amphotericin B.
@en
A clinical isolate of Candida albicans with mutations in ERG11
@nl
type
label
A clinical isolate of Candida ...... to azoles and amphotericin B.
@ast
A clinical isolate of Candida ...... to azoles and amphotericin B.
@en
A clinical isolate of Candida albicans with mutations in ERG11
@nl
prefLabel
A clinical isolate of Candida ...... to azoles and amphotericin B.
@ast
A clinical isolate of Candida ...... to azoles and amphotericin B.
@en
A clinical isolate of Candida albicans with mutations in ERG11
@nl
P2093
P2860
P50
P356
P1476
A clinical isolate of Candida ...... t to azoles and amphotericin B
@en
P2093
Claire M Martel
Diane E Kelly
Michael Weig
Steven L Kelly
P2860
P304
P356
10.1128/AAC.00303-10
P407
P577
2010-06-14T00:00:00Z